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Aims Animal models of stenting are mostly limited to larger animals or involve substantial abdominal surgery in rodents.
We aimed to develop a simple, direct model of murine stenting.
Methods
and results
We designed a miniature, self-expanding, nitinol wire coil stent that was pre-loaded into a metal stent sheath. This
was advanced into the abdominal aorta of the mouse, via femoral access, and the stent deployed. In-stent restenosis
was investigated at 1, 3, 7, and 28 days post-stenting. The model was validated by investigation of neointima formation
in mice deﬁcient in signalling via the interleukin-1 receptor (IL-1R1), compared with other injury models. Ninety-two
per cent of mice undergoing the procedure were successfully stented. All stented vessels were patent. Inﬂammatory
cells were seen in the adventitia and around the stent strut up to 3 days post-stenting. At 3 days, an early neointima
was present, building to a mature neointima at 28 days. In mice lacking IL-1R1, the neointima was 64% smaller than
that in wild-type controls at the 28-day timepoint, in agreement with other models.
Conclusion This is the ﬁrst description of a successful model of murine in situ stenting, using a stent speciﬁcally tailored for use in
small thin-walled arteries. The procedure can be undertaken by a single operator without the need for an advanced
level of microsurgical skill and is reliable and reproducible. The utility of this model is demonstrated by a reduction in
in-stent restenosis in IL-1R1-deﬁcient mice.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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1. Introduction
In vivo models of stenting have been limited to large and medium-
sized animals, such as pigs and rabbits, with the porcine model of
stenting accepted as the ‘gold standard’ pre-clinical model.
1,2 A
limitation of the latter is that ‘normal’ pigs do not suffer from ather-
osclerosis, even when fed a high-fat diet. In comparison, mice are
amenable to genetic manipulation, and ApoE-deﬁcient and LDL
receptor-deﬁcient mice are susceptible to atherosclerosis.
3,4 In
addition, the wide availability of mouse-speciﬁc reagents easily
facilitates basic science research. Until very recently, however,
mice have not been amenable to stent studies due to size
constraints. An arterial stent graft model in the mouse has been
described,
5 although this is limited by the advanced level of micro-
surgical skill required. In addition, this model is not directly com-
parable with the routine stent insertion methods used in the
clinic. Thus, we aimed to develop a simple, direct model of
murine stenting deploying stents in situ. We designed a miniature
self-expanding coil stent for use in the mouse abdominal aorta
and evaluated the vascular response to injury.
Interleukin-1 (IL-1) is an apical mediator in signalling cascades
and has previously been shown to be important in response to vas-
cular injury in mice
6 and pigs.
7 In the latter study, an inhibitor of
IL-1 administered using osmotic pumps reduced in-stent restenosis
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2/2 mice (stock no. 003245) and their genetically matched wild-
type strain, IL-1R1
þ/þ (stock no. 000664), were obtained from the
Jackson Laboratories. Animals were housed in a controlled environ-
ment with a 12 h light/dark cycle at 228C. All experiments were per-
formed in accordance with the UK legislation under the 1986
Animals (Scientiﬁc Procedures) Act, and approval was granted by
the University Ethics Review Board. The investigation conforms
with the Guide for the Care and Use of Laboratory Animals published
by the US National Institutes of Health (NIH Publication No. 85-23,
revised 1996).
2.2 Stent design
A self-expanding coil stent made from nitinol wire (Figure 1A) con-
tained within a hollow tubular steel introducer catheter (custom
made by Brivant Medical Engineering, Galway, Ireland) was used
throughout this study. To deploy, the introducer is retracted over a
pusher allowing the stent to deploy to a coil length of 3 mm and diam-
eter of 1 mm (Figure 2A). As the stent exits the catheter eccentrically,
the tip was blunted with a laser welded bead and a straight ‘leg’ added
to act as a stabilizing strut lying against the vessel wall during deploy-
ment, giving the stent a total length of 4 mm.
2.3 Mouse aortic stent procedure
The stent is placed into the abdominal aorta via femoral access
(Figure 2B). Mice (27–35 g; 4–6 months old) were pre-treated for
Figure 1 The stent design. Scale shows 1 mm (A). The femoral vein and artery are controlled proximally by slings and ligated distally (B).
Making an arteriotomy (C). The stent catheter is inserted into the femoral artery (D) and slowly advanced (E) into the abdominal aorta.
Scale bar represents 350 mm.
A novel mouse model of stenting 3948 h with aspirin (75 mg in 250 ml drinking water) and clopidogrel
(25 mg/kg/day crushed and mixed with sardine). General anaesthesia
was induced with isoﬂurane (maintenance rate of 1.5%) and analge-
sic (0.03 mg/ml vetergesic, s.c.) given. The mouse was positioned
with its left hind limb fully extended and as in line with its spine
as possible so as to create a straight line between femoral artery
and aorta. An incision was made in the groin, and the femoral
artery and vein exposed by blunt dissection. The vessels were
bathed in a solution of 1% lidocaine hydrochloride, and the
femoral nerve dissected free of the artery before the femoral
vein and artery were controlled proximally with slings and ligated
distally with 6/0 silk ties (Figure 1B). Following arteriotomy
(Figure 1C), the stent catheter was inserted into the femoral
artery (Figure 1D and E) and slowly advanced into the abdominal
aorta. Insertion into the aorta was performed without visual gui-
dance. However, measurement of dissected specimens of similar
weights showed that the renal arteries were just over 20 mm
from the groin. Thus, the stent catheter was inserted to a distance
of 20 mm. The stent was deployed and the catheter withdrawn
before ligation of the femoral artery proximal to the arteriotomy,
the wound closed, and the animals allowed to recover. Double anti-
platelet therapy was continued post-operatively until harvest.
As a control, sham-stent procedures (n ¼ 6) were also performed,
following the stent protocol but without deployment of a stent.
2.4 Tissue processing and histological
analysis
Animals (n ¼ 8–12 per timepoint) were killed and perfusion ﬁxed 1 h,
1, 3, 7, and 28 days post-stenting. Stented sections were embedded in
glycol methacrylate resin (Technovit 8100, TAAB laboratories) or
modiﬁed Wolf methacrylate resin
8 (refer Supplementary material
online) and transverse sections, 10 mm thick, made using an Isomet
5000 diamond tipped saw and Metaserv 2000 grinder/polisher
(Buehler). Morphometric analysis was performed on H&E and EVG
stained sections, using Lucia digital analysis software.
Each aorta generated two to three sections of sufﬁcient quality for
analysis, all of which were used in neointimal area analysis.
2.5 Immunohistochemical analysis
Immunohistochemical analysis was performed to determine endo-
thelial cells (vWF, Dako, UK), inﬂammatory cells (mac-387, Dako),
and smooth muscle cells (a-smooth muscle actin, Dako). Slides
embedded in modiﬁed Wolf methylmethacrylate were deacrylated in
xylene and 2-methoxyethylacetate, followed by rehydration in
acetone and water, or rehydrated in ethanol, followed by a water
wash for sections embedded in T8100 resin, prior to staining.
Antigen retrieval, by heating to 808C for 20 min in citrate buffer,
pH6, was performed for vWF and mac-387 staining. Sections were
incubated with primary antibody for 3 h at 378C in PBS containing
10% normal serum. Positive staining was visualized using the ABC tech-
nique followed by New Fuschin. Sections were dry mounted using
superglue, without counterstaining. Further details on antibody
dilutions and incubation times for each stain are given in Supplemen-
tary material online, Table S1.
2.6 Statistics
Data are presented as mean+SEM. Timecourse data were analysed
using a one-way ANOVA followed by a Bonferroni post test. A Stu-
dent’s t-test was used for comparison of IL-1R1
2/2 vs. IL-1R1
þ/þ
neointima formation. P , 0.05 was considered signiﬁcant.
3. Results
Several prototypes of stent were designed, developed, and tested.
The ﬁnal design was a coil with external diameter 1.0 mm, length
3.0 mm, and a low pitch; the latter reducing the number of
rotations made by the stent during deployment. As the stent
exits the catheter eccentrically and caused perforation of the
vessel with initial prototypes, the tip was blunted with a laser
welded bead, and a 1.0 mm straight ‘leg’ added to act as a stabilizing
strut lying against the vessel wall during deployment, giving the
stent a ﬁnal length of 4.0 mm.
The stent was developed and tested in 42 animals. The ﬁnal
design was then deployed in 76 mice, with 69 resulting in successful
recovery of a stented aorta. All arteries were patent upon harvest.
The 9% of animals that failed were lost due to procedural pro-
blems. These involved failure of the stent to deploy from the cath-
eter (four animals), failure to insert the catheter into the
arteriotomy (two animals), and stent migration into the abdominal
cavity (one animal).
The stent procedure can be undertaken with conﬁdence after
training on approximately six mice and takes 30 min to complete,
in the hands of an experienced operator, with minimal blood loss.
Excessive blood loss is controlled by slings providing a temporary
Figure 2 Schematic diagram of stent deployment (A) and pro-
cedure (B). (A): (1) The straightened nitinol wire stent inside the
catheter, with pusher wire, ready for insertion into the animal. (2)
At point of deployment, catheter is retracted over the pusher
wire to deploy the stent. The nitinol wire re-coils using shape
memory. (3) Fully deployed stent. (B) The femoral artery is
exposed and ligated distal from the aorta. Blood ﬂow is tempor-
arily stopped in the femoral using a sling and the stent catheter
inserted through an arteriotomy. The catheter is pushed into
the abdominal aorta before stent deployment. The catheter is
then removed and the proximal femoral artery ligated.
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inserted into the femoral artery, blood loss is prevented by the
oversizing of the catheter compared with the vessel. A small
amount of blood does ﬂow through the catheter itself, but this
is minimal (less than 5 mL).
The procedure has two areas where difﬁculty might occur. First,
negotiating the bend between the femoral artery and aorta can be
problematic. This is resolved by ensuring the mouse hind leg is as
in line with the spine as possible during the procedure to create a
straight line between the vessels. Also the outer diameter of the
delivery catheter is critical: the tip of the stent protrudes from the
cathetertoaidinsertionintothearteriotomy,anddeliverycatheters
withasmallouterdiameterhaveprovenmorelikelytohitresistance
at the femoral/aorta branch, possibly due to the mechanics of the
tube not holding the aorta wall off the stent itself during insertion.
The second procedural problem encountered is permanent leg
paralysis in the mouse on recovery. This occurred in 22% of all
mice undergoing the procedure, with a higher incidence (13%)
during the initial development of the technique. Permanent paraly-
sis is avoided by minimal manipulation of the femoral nerve during
the procedure and ensuring the nerve is not caught up in any
sutures of the vessels. Temporary paralysis of the hind leg upon
immediate recovery is more common (29% of all mice) and is
caused by the use of the local anaesthetic lidocaine hydrochloride
during the procedure. The animals recover from this paralysis
within 30–60 min post-procedure.
Evaluation of the timecourse of stenting showed a progressive
development of neointima (Figures 3A and 4 and see Supplementary
material online, Figure S1). At 1 day after stenting, polymorphonuc-
learcellsareseenaroundtheedgeofthestent (Figure4B).Inﬂamma-
torycellsarealsoseenbeneaththestent,intheadventitia.Thrombus
formation, containing macrophages, is also evident (Figure 5A). A
smooth neointimal accumulation was observed associated with the
stent by 3 days. At 7 days, endothelial cells were seen lining the
neointima (Figure 4D and 5B), which was still associated mainly
with the stent. At 28 days post-stenting, however, a crescentic,
organized, and mature neointima, consisting of smooth muscle
cells, was seen (Figures 4 and 5). In contrast, sham-stented animals
did not develop a neointima in their aorta after 28 days (Figure 4A).
Neointimal area along the length of the each part of the aorta con-
taining the coil stent was not signiﬁcantly variable (minimum: 0.046,
maximum: 0.064 mm
2; median: 0.059, SD: 0.008). Internal elastic
lamina (IEL) area, mean strut area of each section, and medial
thickness remained constant throughout the timecourse (data not
shown). There was no change in body weight using this model.
To determine the usefulness of the mouse aortic stent model in
interventional studies, we examined neointimal formation, 28 days
post-stenting, in stented animals that were unable to signal via IL-1.
IL-1R1
2/2 mice subjected to aortic stenting developed signiﬁcantly
less neointima than their wild-type control (Figure 3B). Medial
thickness, total vessel area, and mean stent strut area did not
differ between these two groups.
4. Discussion
This is the ﬁrst description of a mouse model of in situ stenting,
using a stent speciﬁcally tailored for use in small thin-walled
arteries. The model is a reliable and reproducible procedure that
can be undertaken by a single operator without the need for an
advanced level of microsurgical skill. All the vessels are patent at
28 days post-stenting, and a gradual accumulation of neointima is
seen over the timecourse of 28 days, which is similar to the
pattern seen in other rodent, rabbit, and pig models.
5,9–21 In
addition, neointimal formation in stented animals that are deﬁcient
in IL-1 signalling is reduced compared with control animals, in
agreement with studies using different models of arterial injury
and other animal models of stenting.
6,7 Thus, the model described
here is comparable with others currently in use and will be useful
in interventional studies.
The stent used in our model is made from nitinol, a nickel tita-
nium alloy that has shape memory. Thus, the stent is a self-
expanding coil that reshapes, upon deployment, from the straight
wire loaded into the introducer. Such a stent was in common
use in human studies in the 1990s, although concerns were
raised over toxicity to vascular smooth muscle cells on corrosion
22
and the capacity of the stent to continue to expand after deploy-
ment.
23 In our model, toxicity due to corrosion is not a concern,
unless an extended timepoint is investigated, and the constant
IEL area of sections throughout the timecourse of stenting,
observed in our study, suggests that continued expansion is not
occurring.
Figure 3 A neointima develops progressively over time (A).
Mice deﬁcient in IL-1R1 develop signiﬁcantly less neointima com-
pared with wild-type control at 28 days post-stenting (B).
A novel mouse model of stenting 41Figure 4 Sham stented animals do not develop a neointima at 28 days (A). Polymorphonuclear cells are seen around the stent strut at 1 day
post-stenting (B). A small neointima begins to form at 3 days (C). Endothelialization of the neointima is seen at 7 days (D). A mature neointima is
seen at 28 days (E and F). Image G is a high power of the boxed area in F, stained with elastic van Gieson. Purple luminal stain is an artefact
caused by the T8100 resin. Open triangles depict the IEL; ﬁlled triangles the external elastic lamina, S marks the stent. Scale bar represents
50 mm.
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a difﬁculty with analysis of sections using this model. However, the
mean strut area of each section remains constant, as does the
variability in neointima between sections. Thus, there is no signiﬁ-
cant variation between sections, despite the eccentric lesion in
relation to the spiral shape of the stent, meaning that the model
is both reproducible and reliable.
Mice are small, inexpensive, and easy to handle, making them
ideal for use in disease models. Mice are also amenable to
genetic manipulation and can be rendered susceptible to athero-
sclerosis.
3,4 Therefore, a mouse stent model will allow more
detailed investigation into the development of in-stent restenosis
following stenting of a diseased vessel. The mouse carotid is the
best characterized vessel in models employing surrogate injuries,
but is too small to stent. The aorta, like the carotid, is an elastic
artery and is over twice the diameter of the carotid. The aorta,
therefore, is currently the vessel of choice for a mouse stent
model.
The aorta is also used in several rat models of stenting.
11–14 All
these models use a commercially available balloon expandable
stent rather than the coil stent used in our model. Two models
involve substantial abdominal surgery, deploying the stent directly
into the abdominal aorta via arteriotomy,
11,13 another deploys the
stent into the thoracic aorta via carotid artery access,
12 and a
fourth deploys the stent in the abdominal aorta via femoral
access in a procedure similar to the one described in our mouse
model.
14 All these models report a failure rate of 8–15%, which
is comparable to the 10% rate of our model. The neointima for-
mation in all these models is modest and develops slowly over
time, with the neointima mainly associated with the stent strut
up to 7 days post-procedure. Inﬂammation is also apparent, associ-
ated with the stent struts, in these models up to 3 days after place-
ment of the stent. This is directly comparable to our mouse model,
which also has stent-associated inﬂammation and a small neointima
that is initially associated with the stent before becoming a mature,
concentric neointima at 28 days.
Only one other model of mouse stenting has been developed.
5
This model deploys a balloon expandable stent into the thoracic
aorta of a donor mouse, which is subsequently grafted into the
carotid circulation of a recipient mouse. This model demands a
high level of microsurgical skill and uses two mice for each pro-
cedure. Our model, in contrast, employs a more simple technique
in which a self-expanding stent is deployed ‘directly’ into the aorta
of the mouse under investigation. Thus, the stent is deployed in situ,
without complicating features of transplantation and marked
changes in vessel diameter and ﬂow dynamics. In addition, although
our model involves an initial steep learning curve (equivalent to
other reported models), it has a high rate of success (92% survival
rate compared with 80–90% reported by other small animal
models) and all vessels were patent on harvest.
Figure 5 Immunohistochemical staining showing inﬂammatory cells trapped in a transient thrombus and on the stented surface (arrowed) at
3 days (A), endothelial cells lining the lumen at 7 days (B), and smooth muscle cells of the media and neointima at 28 days post-stenting (C and
D). Open triangles depict the IEL; ﬁlled triangles the external elastic lamina; and S denotes stent metal. Scale bar represents 100 mm.
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other methods utilizing sections with the stent remaining in situ. The
thickness of the stent sections obtained, along with the fact that
the spiral coil stent rises out of the tissue in each section, leads to
a difﬁculty in obtaining high-quality images. In addition, immunohis-
tochemical staining is limited in tissue embedded in methylmetha-
crylate resin, which is further exacerbated by the thickness of the
section obtained. This limits the ability to characterize events
causingin-stentrestenosisinthismodelandcouldlimititsusefulness
to investigations of efﬁcacy of potential treatments. However,
despite the limitations on immunostaining, we have managed to
achievepositivestainingforsmoothmuscle,inﬂammatoryandendo-
thelial cells, depending on the methylmethacrylate resin used,
antigen retrieval, and an altered incubation protocol from the stan-
dard used with wax-embedded sections.
The usefulness of this model in interventional studies is shown
by the response to stenting of mice deﬁcient in IL-1 signalling, com-
pared with wild-type mice. We have previously shown that these
mice develop a signiﬁcantly reduced neointima in response to
carotid ligation injury,
6 a response that is duplicated using our
stent model. Bone marrow transplant experiments in these mice
suggest IL-1 signalling in both vascular wall cells and circulating
(inﬂammatory and progenitor) cells play an equal role in neointima
formation following carotid ligation,
6 and it is likely that the same
mechanism is involved in in-stent restenosis, following stenting of
these mice.
In conclusion, we have established a new model of in situ murine
stenting. The model mimics features of neointimal formation in the
human, and replicates those of other animal stent models. Thus,
the model will allow investigation into molecular pathways in
in-stent restenosis (using transgenic or chimeric mice), as well as
novel anti-restenosis strategies.
Supplementary material
Supplementary material is available at Cardiovascular Research
online.
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